{"TopicDetails": {"type": 0, "ccm2Id": 44320972, "cftId": 0, "identifier": "EU4H-2021-PJ-12", "title": "Action grants to create a \u2018Cancer Survivor Smart Card\u2019", "publicationDateLong": 1634083200000, "callIdentifier": "EU4H-2021-PJ2", "callTitle": "Project grants wave 2", "callccm2Id": 44321039, "allowPartnerSearch": true, "workProgrammepart": {"id": 5874, "ccm_id": 44188220, "wp_part": "EU4H-2021", "wp_year": "EU4H-2021", "wp_title": "EU4H-2021", "wp_website": "https://ec.europa.eu/health/", "wp_document": "https://ec.europa.eu/health/funding/eu4health_en"}, "frameworkProgramme": {"id": 43332642, "abbreviation": "EU4H", "description": "EU4 Health Programme (EU4H)"}, "programmeDivision": [{"id": 43332657, "abbreviation": "Health", "description": "Improving and fostering health in the Union to reduce the burden of communicable and non-communicable diseases"}, {"id": 43332653, "abbreviation": "EU4H-1", "description": "EU4H-1"}], "topicMGAs": [], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "EU4H-PJG EU4H Project Grants", "typeOfMGA": [{"id": 43326018, "abbreviation": "EU4H-AG", "description": "EU4H Action Grant Budget-Based"}]}], "plannedOpeningDate": "14 October 2021", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["25 January 2022"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3382142": [{"action": "EU4H-2021-PJ-12 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 1800000}, "budgetTopicActionMap": {}}], "3382144": [{"action": "EU4H-2021-PJ-15 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 6000000}, "budgetTopicActionMap": {}}], "3382146": [{"action": "EU4H-2021-PJ-14 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 7000000}, "budgetTopicActionMap": {}}], "3382148": [{"action": "EU4H-2021-PJ-18 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 2500000}, "budgetTopicActionMap": {}}], "3382150": [{"action": "EU4H-2021-PJ-13 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 5000000}, "budgetTopicActionMap": {}}], "3382152": [{"action": "EU4H-2021-PJ-09 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 4400000}, "budgetTopicActionMap": {}}], "3382154": [{"action": "EU4H-2021-PJ-17 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 4000000}, "budgetTopicActionMap": {}}], "3382156": [{"action": "EU4H-2021-PJ-08 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 1200000}, "budgetTopicActionMap": {}}], "3382158": [{"action": "EU4H-2021-PJ-11 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 1200000}, "budgetTopicActionMap": {}}], "3382160": [{"action": "EU4H-2021-PJ-10 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 2000000}, "budgetTopicActionMap": {}}], "3382162": [{"action": "EU4H-2021-PJ-16 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 3000000}, "budgetTopicActionMap": {}}], "3382164": [{"action": "EU4H-2021-PJ-06 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 5000000}, "budgetTopicActionMap": {}}], "3382166": [{"action": "EU4H-2021-PJ-07 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "14 October 2021", "deadlineModel": "single-stage", "deadlineDates": ["25 January 2022"], "budgetYearMap": {"2021": 750000}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2021"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p><strong>POLICY CONTEXT</strong></p><p>Evidence shows that cancer survivors often report difficulties in communicating with oncologists, general practitioners and nurses, and to establish a link with social services, which can be of particular importance to reduce the risk of negative quality-of-life outcomes. Therefore, it is imperative to develop interventions to improve communication between survivors, health and social care providers. The action will be implemented taking into account the assumption that communication between patients and clinicians embraces three core attributes of \u2018patient-centered\u2019 care: (1) consideration of patients\u2019 needs, perspectives, and individual experiences; (2) provision of opportunities to patients to participate in their care (\u2018self-management\u2019); and (3) enhancement of the patient-clinician-nursing relationship.</p><p>This action supports the implementation of Europe\u2019s Beating Cancer Plan objective to improve the quality of life for cancer patients, survivors and carers and links with the European Health Data Space and the European Cancer Patient Digital Centre, and implements the EU4Health Programme\u2019s general objective of improving and fostering health in the Union (Article 3, point (a)) through the specific objectives defined in Article 4, points (a), (f) and (g) of Regulation (EU) 2021/522.</p>\n<SPAN class=\"topicdescriptionkind\">Objective</SPAN>:<p><strong>OBJECTIVES</strong><br></p><p>The aim of the action is to improve the quality of life and health status of cancer survivors, and to address their potential needs through the development and support for the wide use of new approaches to communication.</p><p><span><span>A \u2018Cancer Survivor Smart Card\u2019 will link with a \u2019resource\u2019 function to give access to best practices, guidelines and recommendations specifically targeted to cancer survivors, with a view to helping them to address or to connect with professionals in different areas, to deal with the most common issues that survivors face, such as insufficient management of late and long-term effects of treatment, unmet psychosocial needs, self-management, pain management, and issues related to rehabilitation, emotional distress, tumour recurrence and metastatic disease.</span></span></p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p><strong>DESCRIPTION OF THE ACTIVTIES FUNDED UNDER THIS TOPIC </strong></p><p><span>The action will support the development, delivery and usability of a personalised \u2018Cancer Survivor Smart Card\u2019 by 2022. The smart card, in the form of an interoperable portable eCard or app, will store certain information related to the monitoring and follow-up of the survivor, including the survivor\u2019s clinical history and follow-up. The smart card will allow connection with the health professionals responsible for the individual\u2019s follow-up, including the survivor\u2019s general practitioner, to improve healthcare provider and survivor communication on the survivor\u2019s worries, questions and other matters of relevance to improve the survivor\u2019s quality of life. The action will involve patients\u2019 groups and health and social care providers, in order to apply a participatory and co-creative approach to help with the development of the tool, and to coach a group of \u2018card-users\u2019 to pilot the smart card\u2019s usage once it has been developed, in preparation for the wider application phase. </span></p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p><strong>EXPECTED RESULTS AND IMPACT</strong></p><p><br>The co-creation, piloting, promotion, and use of the \u2018Cancer Survivor Smart Card\u2019 is expected to improve patient-centred communication between cancer survivors and health and social care providers, through the wide use of communication tools and the application of new approaches to communication to improve quality of life, promote healing and reduce suffering.</p><p>This is likely to improve the quality of life of cancer patients, including that of children and young cancer survivors, through dissemination of best practices on issues such as psychological support, self-management, pain management and professional re-integration. The action will also facilitate the portability and the sharing of data from medical records.</p><p><span><span>The action will ensure a shared and equal access to high-quality information and data, and best practices for cancer survivors across the Union. No country can reach the same results alone, in particular considering that survivorship is still an area that requires additional evidence-based information, and that a shared approach will ensure the improvement of the quality of life of cancer survivors.</span></span></p><p><strong><span>SPECIFIC MANDATORY DELIVERABLES AND/OR MILESTONES</span></strong></p><p><span>Participants in the action have to regularly report on the progress of the development, delivery and usability of the Card. </span></p><p><strong><span><span>SPECIFIC ACTION-LEVEL INDICATORS FOR REPORTING PURPOSES</span></span></strong></p><p>Applicants must include data on the following indicators in their regular reporting activities in case of award, and must be prepared to include additional specific indicators where needed:</p><ul level=\"0\"><li>Number of participants involved to pilot the Cancer Survivor Smart Card (breakdown per country, gender and socioeconomic status).</li><li>Estimated number of people who indicated that the Card has improved the communication with their <em>health and social care providers</em> (breakdown per country, gender and socioeconomic status).</li><li>Number of supportive (online) materials for cancer survivors produced and disseminated (breakdown per breakdown per country and target group).</li><li>Number of (validated) best practices identified, collected and shared.</li> </ul>\n", "conditions": "<p><b><span lang=\"EN-US\" style=\"font-size: 12pt; line-height: 18.4px; color: rgb(64, 64, 64);\">Conditions<br />\r\n<br type=\"_moz\" />\r\n</span></b></p>\r\n<p><b><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:&#10;text1;mso-themetint:191;mso-ansi-language:EN-US\">1.&nbsp;</span></b><b><span lang=\"EN-US\">Admissibility conditions: </span></b><span lang=\"EN-US\">described in section 5 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2021/call-fiche_eu4h-2021-pj-02_en.pdf\" target=\"_blank\">call document.</a>&nbsp;</span></p>\n<p><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\">&nbsp;described in section 5 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2021/call-fiche_eu4h-2021-pj-02_en.pdf\" target=\"_blank\">call document</a></span></p>\n<p><b><span lang=\"EN-US\">2. Eligible countries:&nbsp;</span></b><span lang=\"EN-US\">described in section 6 of of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2021/call-fiche_eu4h-2021-pj-02_en.pdf\" target=\"_blank\">call document</a></span></p>\n<p><b><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\">&nbsp;described in section 6 of the <a href=\"http://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/temp-form/af/detailed-budget-table_eu4h_en.xlsm\" target=\"_blank\">call document</a></span></p>\n<p><b>4. Financial and operational capacity and exclusion:&nbsp;</b>described in&nbsp;<span lang=\"EN-US\">section 7 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2021/call-fiche_eu4h-2021-pj-02_en.pdf\" target=\"_blank\">call document</a></span></p>\n<p><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></p>\n<ul>\r\n    <li><b><span lang=\"EN-US\">Award criteria, scoring and thresholds:</span></b><span lang=\"EN-US\">&nbsp;described in section 9 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2021/call-fiche_eu4h-2021-pj-02_en.pdf\" target=\"_blank\">call document</a></span></li>\r\n</ul>\n<ul>\r\n    <li><b><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\">Submission and evaluation processes</span></b><b><span lang=\"EN-US\">:</span></b><span lang=\"EN-US\">&nbsp;described&nbsp;<span style=\"color: rgb(64, 64, 64);\">section 8 of the call document and the</span>&nbsp;</span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span lang=\"EN-US\">Online Manual</span></a></li>\r\n</ul>\n<ul>\r\n    <li><b><span lang=\"EN-US\">Indicative timeline for evaluation and grant agreement:&nbsp;</span></b><span lang=\"EN-US\">described in section 4 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2021/call-fiche_eu4h-2021-pj-02_en.pdf\" target=\"_blank\">call document</a></span></li>\r\n</ul>\n<p><b><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\">6</span></b><b><span lang=\"EN-US\">. Legal and financial set-up of the grants:&nbsp;</span></b><span lang=\"EN-US\">described&nbsp;<span style=\"color: rgb(64, 64, 64);\">in section 10 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2021/call-fiche_eu4h-2021-pj-02_en.pdf\" target=\"_blank\">call document</a></span></span></p>\r\n<p>&nbsp;</p>\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span lang=\"EN-US\" style=\"font-size: 12pt; line-height: 18.4px; color: rgb(64, 64, 64);\">Documents<br />\r\n<br />\r\n<o:p></o:p></span></b><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#10;mso-ansi-language:EN-US\"><b><span lang=\"EN-US\">Call documents:</span></b></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#10;mso-ansi-language:EN-US\"><span style=\"color: rgb(51, 51, 51); font-family: eui-default, Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 14px;\">Text of the EU4HEALTH Call document:&nbsp;</span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2021/call-fiche_eu4h-2021-pj-02_en.pdf\" target=\"_blank\">Call document </a><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"box-sizing: border-box; border: 0px; font-variant-numeric: inherit; font-variant-east-asian: inherit; font-stretch: inherit; line-height: 1.618; font-family: eui-default, Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 14px; margin: 1rem 0px; padding: 0px; color: rgb(51, 51, 51);\"><span lang=\"EN-US\" style=\"box-sizing: border-box; border: 0px; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; line-height: inherit; font-family: inherit; margin: 0px; padding: 0px;\">EU4health standard application form:&nbsp;<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/temp-form/af/af_eu4h_en.pdf\" target=\"_blank\">Standard application form</a>&nbsp;&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"box-sizing: border-box; border: 0px; font-variant-numeric: inherit; font-variant-east-asian: inherit; font-stretch: inherit; line-height: 1.618; font-family: eui-default, Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 14px; margin: 1rem 0px; padding: 0px; color: rgb(51, 51, 51);\"><span lang=\"EN-US\" style=\"box-sizing: border-box; border: 0px; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; line-height: inherit; font-family: inherit; margin: 0px; padding: 0px;\">EU4Health detailed budget:&nbsp;<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/reference-documents;programCode=EU4H\" target=\"_blank\">EU4Health Detailed budget table</a>&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"box-sizing: border-box; border: 0px; font-variant-numeric: inherit; font-variant-east-asian: inherit; font-stretch: inherit; line-height: 1.618; font-family: eui-default, Arial, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 14px; margin: 1rem 0px; padding: 0px; color: rgb(51, 51, 51);\"><span style=\"box-sizing: border-box; border: 0px; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; line-height: inherit; font-family: inherit; margin: 0px; padding: 0px;\">EU4Health Programme:&nbsp;<a href=\"https://ec.europa.eu/health/funding/eu4health_en\" target=\"_blank\">EU4Health programme</a>&nbsp;</span></p>\n<p><span lang=\"EN-US\" style=\"line-height: 15.3333px; color: rgb(64, 64, 64);\">EU4Health:</span><span lang=\"EN-US\" style=\"font-size: 10pt; line-height: 15.3333px; font-family: &quot;Segoe UI&quot;, sans-serif; color: rgb(64, 64, 64);\">&nbsp;</span><span class=\"MsoHyperlink\"><span style=\"color: rgb(64, 64, 64);\">&nbsp;<a href=\"https://ec.europa.eu/health/funding/eu4health_en\" target=\"_blank\">2021 Annual Work Programme</a></span></span></p>\r\n<p><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\">EU4Health Regulation:&nbsp;</span><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\">&nbsp;<a href=\"https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2021.107.01.0001.01.ENG\" target=\"_blank\">Regulation 2021/522</a></span></p>\r\n<p>EU financial Regulation:&nbsp;<a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\"><span lang=\"EN-US\">EU Financial Regulation 2018/1046</span></a></p>", "supportInfo": "<p><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">For help related to this</span><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">&nbsp;</span><b style=\"font-family: Arial, sans-serif; font-size: 9pt;\">call</b><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">, please contact:</span><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">&nbsp;</span>HaDEA-HP-CALLS@ec.europa.eu</p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;grantAndTendertype=1;categories=p_submission_eval;programme=null;actions=;keyword=;period=null\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Funding &amp; Tenders Portal FAQ</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Submission of proposals.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">IT Helpdesk</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Contact the IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://webgate.ec.europa.eu/funding-tenders-opportunities/display/OM/Online+Manual\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Online Manual</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Step-by-step online guide through the Portal processes from proposal preparation and submission to reporting on your on-going project. Valid for all 2021-2027 programmes.</span></p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "<p>&nbsp;On 24 March 2021, the EU4Health Regulation was adopted as part of the EU Multiannual Financial Framework for the 2021-2027 period. The EU4Health Regulation established &lsquo;the EU4Health Programme&rsquo;. This marks an important step towards making available instruments and solutions to support Member States in building stronger, more resilient and accessible health systems.</p>\r\n<p>The EU4Health Programme represents an unprecedented level of financial commitment for the EU in health in comparison with previous health programmes. The Programme is EU&rsquo;s response to the current public health emergency that will make a significant contribution to the post-COVID-19 recovery aiming to:<br />\r\n- improve public health in the Union through disease prevention and health promotion, as well as international health initiatives and cooperation;<br />\r\n- protect people from serious cross-border health threats through prevention, preparedness and response to cross-border health threats; complementing national stockpiling of essential crisis-relevant products; and establishing a reserve of medical, healthcare and support staff;<br />\r\n- improve access to medicinal products, medical devices and crisis-relevant products by encouraging sustainable production and supply chains and innovation in the Union and efficient use of medicinal products;<br />\r\n- strengthen the national health systems through improved health data use and re-use, development of digital tools and services, digital transformation of healthcare; enhancing access to healthcare; developing and implementing EU health legislation and evidence-based decision making; and integrated work among Member States&rsquo; health systems.</p>\r\n<p>Cancer is the second leading cause of mortality in the Member States after cardiovascular disease. The prevention and control of cancer would benefit the majority of citizens since it shares common risk factors with other non-communicable diseases. Europe&rsquo;s Beating Cancer Plan, which is a key pillar of a stronger European Health Union, tackles the entire cancer disease pathway by means of flagship initiatives, such as launching a Cancer Inequalities Registry, and supporting actions, such as establishing an EU Network of Youth Cancer Survivors. The EU4Health programme will provide the financial support to implement these initiatives that are important to mitigate the impact of the COVID-19 pandemic on cancer control and care.</p>\r\n<p>Grants shall involve co-financing. Grants paid by the Union shall not exceed 60 % of eligible costs for an action relating to an objective of the Programme. In cases of exceptional utility, the contribution by the Union may be up to 80 % of eligible costs.</p>\r\n<p>&nbsp;</p>", "staticAdditionalInfo": "", "latestInfos": [{"approvalDate": "Oct 26, 2022 11:38:58 AM", "lastChangeDate": "Oct 26, 2022 11:38:58 AM", "content": "<p class=\"MsoNormal\"><span style=\"font-size:10.5pt;line-height:115%;font-family:&#10;&quot;inherit&quot;,serif;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&#10;Arial;color:#333333;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;&#10;padding:0cm;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">A total of 55 </span><b><span style=\"font-size:10.5pt;line-height:115%;font-family:&quot;inherit&quot;,serif;&#10;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Helvetica;&#10;color:#333333;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;&#10;padding:0cm;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">proposals have been submitted&nbsp;</span></b><span style=\"font-size:10.5pt;line-height:115%;&#10;font-family:&quot;inherit&quot;,serif;mso-fareast-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-font-family:Arial;color:#333333;border:none windowtext 1.0pt;&#10;mso-border-alt:none windowtext 0cm;padding:0cm;mso-ansi-language:EN-IE;&#10;mso-fareast-language:EN-IE\">in response to this call.</span><span lang=\"EN-GB\"><o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-06: 1 proposal<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-07: 2 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-08: 2 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-09: 11 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-10: 2 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-11: 1 proposal<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-12: 2 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-13: 12 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-14: 5 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-15: 6 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-16: 3 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2021-PJ-17: 3 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span style=\"font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]-->EU4H-2021-PJ-18: 5 proposals<o:p></o:p></p>"}, {"approvalDate": "Oct 14, 2021 12:00:00 AM", "lastChangeDate": "Oct 14, 2021 12:00:00 AM", "content": "The submission session is now available for: EU4H-2021-PJ-06(EU4H-PJG), EU4H-2021-PJ-08(EU4H-PJG), EU4H-2021-PJ-07(EU4H-PJG), EU4H-2021-PJ-16(EU4H-PJG), EU4H-2021-PJ-10(EU4H-PJG), EU4H-2021-PJ-15(EU4H-PJG), EU4H-2021-PJ-09(EU4H-PJG), EU4H-2021-PJ-12(EU4H-PJG), EU4H-2021-PJ-11(EU4H-PJG), EU4H-2021-PJ-14(EU4H-PJG), EU4H-2021-PJ-13(EU4H-PJG), EU4H-2021-PJ-18(EU4H-PJG), EU4H-2021-PJ-17(EU4H-PJG)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}